Versartis seeks to help the short-statured. The development-stage biopharmaceutical company has a single drug in development: VRS-317, a long-acting recombinant human growth hormone (HGH) for the treatment of growth hormone deficiency (GHD) in children. While recombinant treatments for GHD (an orphan disease) already exist, they require daily injections, while VRS-317 does not. (The company is evaluating weekly, semi-monthly, and monthly dosing regimens.) The drug is currently being studied in children in phase 3 clinical trials. A treatment for adults is a longer-term prospect. Founded in 2008, Versartis went public in 2014.